Literature DB >> 7730480

Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.

J M van Es1, M M Polak, F M van den Berg, T B Ramsoekh, M E Craanen, R H Hruban, G J Offerhaus.   

Abstract

AIMS: To determine the potential efficiency of molecular markers specific for neoplastic change--mutations of the K-ras oncogene and the p53 tumour suppressor gene--in diagnosing pancreatic carcinoma.
METHODS: Archival cytology samples obtained from 17 patients with established pancreatic carcinoma were assayed for alterations in K-ras and p53. To detect changes in p53 expression, immunocytochemistry with polyclonal antibody CM1 was performed on the archival cytology slides after destaining. Mutations in K-ras codon 12 were then analysed on the scrapings of the same slides using mutant enriched polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism analysis with allele specific oligonucleotide hybridisation for confirmation and characterisation.
RESULTS: False negative results were recorded for five of the cytology slides when compared with p53 immunostaining of the surgical resection specimen. These five cases had been stained previously with Giemsa which interacts adversely with the immunostaining in contrast to the Papanicolaou procedure. The K-ras codon 12 mutations followed the well established distribution frequency and spectrum for pancreatic cancer and corresponded with the findings in the resection specimens in all cases. Two scrapings yielded insufficient DNA for PCR. Importantly, for two cases with an inconclusive cytology diagnosis on routine light microscopy, the diagnosis was confirmed by one of the molecular markers. The application of the molecular markers increased the diagnostic accuracy of cytology in this small study from 76 to 89%.
CONCLUSIONS: The study indicates that assessment of alterations in the K-ras and p53 genes may be a valuable adjunct to diagnostic cytopathology of the head region of the pancreas, although there are some difficulties which will have to be overcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730480      PMCID: PMC502447          DOI: 10.1136/jcp.48.3.218

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  p53 immunostaining as a marker of malignant disease in diagnostic cytopathology.

Authors:  P A Hall; A Ray; N R Lemoine; C A Midgley; T Krausz; D P Lane
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas.

Authors:  D Shibata; C Almoguera; K Forrester; J Dunitz; S E Martin; M M Cosgrove; M Perucho; N Arnheim
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

Review 5.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.

Authors:  I O Baas; J W Mulder; G J Offerhaus; B Vogelstein; S R Hamilton
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

8.  Expression of the nuclear oncogene p53 in colon tumours.

Authors:  F M van den Berg; A J Tigges; M E Schipper; F C den Hartog-Jager; W G Kroes; J M Walboomers
Journal:  J Pathol       Date:  1989-03       Impact factor: 7.996

9.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.

Authors:  M Verlaan-de Vries; M E Bogaard; H van den Elst; J H van Boom; A J van der Eb; J L Bos
Journal:  Gene       Date:  1986       Impact factor: 3.688

10.  Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

Authors:  C M Barton; S L Staddon; C M Hughes; P A Hall; C O'Sullivan; G Klöppel; B Theis; R C Russell; J Neoptolemos; R C Williamson
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

View more
  11 in total

1.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients.

Authors:  R H Hruban; P D Sturm; R J Slebos; R E Wilentz; A R Musler; C J Yeo; T A Sohn; M L van Velthuysen; G J Offerhaus
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; R Kucway; W Du; D S Kamarauskiene; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-04

Review 4.  Molecular diagnosis of pancreas carcinoma.

Authors:  T M Chu
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Clinical significance of K-ras oncogene activation in ampullary neoplasms.

Authors:  C H Chung; R E Wilentz; M M Polak; T B Ramsoekh; L A Noorduyn; D J Gouma; K Huibregtse; G J Offerhaus; R J Slebos
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

6.  Brush cytology in the assessment of pancreatico-biliary strictures: a review of 406 cases.

Authors:  C J Stewart; P R Mills; R Carter; J O'Donohue; G Fullarton; C W Imrie; W R Murray
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

7.  Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.

Authors:  D S Weinberg; B Ruggeri; M T Barber; S Biswas; S Miknyocki; S A Waldman
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

8.  Early diagnosis of pancreatobiliary duct malignancies by brush cytology and biopsy.

Authors:  Gábor Elek; Tibor Gyökeres; Eszter Schäfer; Mária Burai; Ferenc Pintér; Akos Pap
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

9.  Unexpected benign histopathology after pancreatoduodenectomy for presumed malignancy: accepting the inevitable.

Authors:  Rachel M Gomes; Munita Bal; Shraddha Patkar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2016-01-26       Impact factor: 3.445

10.  K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination.

Authors:  K Yamashita; Y Kida; H Shinoda; M Kida; I Okayasu
Journal:  Jpn J Cancer Res       Date:  1999-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.